J Korean Ophthalmol Soc > Volume 52(9); 2011 > Article
Journal of the Korean Ophthalmological Society 2011;52(9):1055-1062.
DOI: https://doi.org/10.3341/jkos.2011.52.9.1055    Published online September 15, 2011.
Electroretinographic Assessment of the Retinal Function during Intravitreal Bevacizumab Injections in Central Retinal Vein Occlusion.
In Hwan Cho, Tae Kwann Park, Young Hoon Ohn
Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea. genophilus@hanmail.net
망막중심정맥폐쇄에서 유리체강내 베바시주맙 주사 전 후에 망막전위도를 통한 망막기능의 평가
조인환⋅박태관⋅온영훈
Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
Abstract
PURPOSE
To investigate the changes of electroretinogram (ERG) at baseline and during the first 3 injections of intravitreal bevacizumab in central retinal vein occlusion (CRVO) patients. METHODS: Thirteen eyes of 13 CRVO patients who received 3 injections of intravitreal bevacizumab at 6-week intervals and who could be examined for visual acuity, optical coherence tomography and ERG at 4 weeks after each injection were included in the present study. In addition, the ERG results of the unaffected fellow eyes group at 4 weeks after each injection were compared with the CRVO eyes group. RESULTS: Amplitudes of rod b wave, a and b waves of maximal combined response and cone response, oscillatory potentials and 30-Hz flicker significantly decreased in the CRVO eyes group than the fellow eyes group at 4 weeks after each injection (p < 0.001). After injection, amplitudes of all the above-mentioned ERG parameters gradually increased during the 1st and the 2nd injection (p < 0.001). However, there was no significant difference at 4 weeks after the 2nd and 3rd injections (p > 0.05). CONCLUSIONS: After intravitreal bevacizumab injection, macular functions significantly improved and amplitudes of all ERG parameters gradually increased in CRVO patients.
Key Words: Central retinal vein occlusion;Electroretinogram;Intravitreal bevacizumab injection


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next